Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

STTK vs MTNB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–0 Matrix Metrics)

STTK Overall Winner 6-Pillar Tally: STTK 3 – 1 MTNB (2 Tie) Matrix Metrics: STTK 6 – 0 MTNB

As of Nov 19, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). STTK carries a Unified Composite Score of 58.4/100 (HOLD) at $4.55 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STTK vs MTNB
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.55
+1.79% 1D
Market Cap $459.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.46β · 68% Vol
Unified Composite Score
58.4 / 100 HOLD
Tech 82.0 Fund 50.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.1%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $5.08 · SMA50: $5.65
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47

6-Pillar Scorecard Institutional Category Breakdown (STTK 3 – 1 MTNB)

Columns: Metric · STTK · MTNB
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale STTK
Revenue Growth (YoY) -66.6% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $459.8M $979,904
3. Profitability & Quality STTK
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -47.2% -147.5%
4. Balance Sheet & Cash Flow MTNB
Cash Generation (TTM) -$50M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $59M Net Cash $1.2M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STTK
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 72.4% (10th %ile) N/A (N/A)
Put/Call OI Skew 4.66x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STTK (6) vs MTNB (0)
Institutional Metric STTK MTNB Criterion Row Edge
Market Capitalization
Scale
$459.8M $979,904 Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-66.6% -100.0% Higher Growth STTK
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-47.2% -147.5% Higher ROE STTK
52-Week Range Position
Momentum
41% ($2–$8) 22% ($0–$3) Stronger Trend STTK
Beta / 30D Volatility
Risk Regime
1.46β · 68% Vol -7.20β · 147% Vol Lower Realized Risk STTK
Unified Institutional Score
Composite Signal
58.4 / 100 (HOLD) 54.6 / 100 (HOLD) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M ($59M Net Cash) N/A ($1.2M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STTK +28.24 pp
STTK: -18.46% · MTNB: -46.7%
3M Horizon MTNB +347.07 pp
STTK: -39.58% · MTNB: +307.49%
6M Horizon MTNB +46.22 pp
STTK: -25.29% · MTNB: +20.93%
1Y Horizon STTK +157.72 pp
STTK: +126.37% · MTNB: -31.35%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period STTK Revenue MTNB Revenue STTK Op. Margin MTNB Op. Margin Margin Leader
FY2018 N/A $0M N/A -12230.9% MTNB
FY2019 $10M $0M -253.5% -21067.4% STTK
FY2020 $10M $0M -371.8% -15288.4% STTK
FY2021 $30M $0M -150.8% -74954.5% STTK
FY2022 $0M $0M -15848.0% -771.3% MTNB
FY2023 $0M $0M -5549.6% -2168.4% MTNB
FY2024 $10M N/A -1408.3% N/A STTK
FY2025 $0M N/A -5150.8% N/A STTK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STTK BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.66x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $459.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STTK vs MTNB Key Questions & Quantitative Answers

As of Nov 19, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). STTK carries a Unified Composite Score of 58.4/100 (HOLD) at $4.55 (N/M Forward P/E, 0.0% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STTK leads the Growth & Scale pillar: STTK posts -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), STTK cumulative revenue shifted +0.0% while MTNB shifted N/A. In operating R&D and SG&A reinvestment, STTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.

STTK and MTNB trade at balanced relative valuation multiples. STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STTK (-47.2% ROE) versus MTNB (-147.5% ROE) capital efficiency.

In options market volatility and institutional positioning, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.66x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 68% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.